Sanofi-Aventis (SNY:NYSE; $38.10; 2,500 shares; 3.01%; Sector: Health Care): Sanofi Pasteur, the company's vaccine division, announced that the FDA has approved its supplemental biologics license application for licensure of Fluzone Intradermal. The vaccine fights influenza virus subtypes A and B and is suitable for adults 18 through 64. This announcement was expected and highlights the company's effort to grow beyond just pharmaceuticals and into faster-growing segments -- vaccines, diabetes, generics and animal/consumer health. The trough year in earnings is coming in 2012, with Plavix/Iscover, Taxotere, Avapro/Avalide and Ambien CR all going off patent -- but beyond this well-expected period, the company has positioned itself for 5%-7% growth from 2013 to 2015. It has two analyst meetings upcoming (June 28 and Sept. 6) that will likely be positive catalysts for the shares. At 8x earnings, the stock remains attractive. I bought more this week and will continue to build up the position. My target is $45.